"Oncorus' novel technology is generating a pipeline of uniquely engineered viruses and first-in-class vRNA product candidates. I'm excited to partner with this exceptional team to progress their portfolio of viral immunotherapies and unlock the potential of this modality to activate multiple arms of the immune system, realizing the promise of this new class of medicines in oncology," said Dr. Fambrough. "I look forward to working with my fellow board members and Oncorus' leadership team to advance this potentially paradigm-shifting approach to cancer treatment."